Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis

Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a...

Full description

Bibliographic Details
Main Authors: Yves Michiels, Nadhira Houhou-Fidouh, Gilles Collin, Jérôme Berger, Evelyne Kohli
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Vaccines
Subjects:
SARS-CoV-2
mRNA1273 vaccine
antibody response
methotrexate
adalimumab
Online Access:https://www.mdpi.com/2076-393X/9/8/883

Similar Items

Similar Items